Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: PreDiabetes, Diet, Healthy, Nutritional and Metabolic Diseases
Interventions: Whole Foods for Families; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 6 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: MDS
Interventions: APR-246 + azacitidine, Azacitidine; Drug
Lead sponsor: Aprea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Duarte, California • Palo Alto, California • New Haven, Connecticut + 17 more

Conditions: Obesity, Labor, Induced, Oxytocin
Interventions: Oxytocin; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Knee Osteoarthritis
Interventions: Ascent, Standard; Procedure
Lead sponsor: StimLabs; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Brookhaven, Georgia • Dunwoody, Georgia • Johns Creek, Georgia + 1 more

Conditions: Myositis, Interstitial Lung Disease
Interventions: Abatacept, Placebo; Drug · Other
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Lupus Erythematosus, Systemic
Interventions: Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Appetitive Behavior
Interventions: Snack, No Snack; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Menopause Related Conditions
Interventions: Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose; Dietary Supplement
Lead sponsor: Hofseth Biocare ASA; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 310
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more

Conditions: Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
Interventions: Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g); Drug · Other
Lead sponsor: Bradley Nindl; Other
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cataract, Down Syndrome
Interventions: cataract surgery; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Month to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Milk and/or Peanut Allergy
Interventions: Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk); Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Methamphetamine Use Disorder
Interventions: Tirzepatide, Placebo (saline); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more

Conditions: Gastroesophageal Reflux
Interventions: XP19986 SR3, 20 mg QD, XP19986 SR3, 40 mg QD, XP19986 SR3, 60 mg QD, XP19986 SR3, 30 mg BID, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Irvine, California

Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 17,802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 431
States / cities: Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more

Conditions: Abdominal Pain
Interventions: Placebo, HBB 20 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 19
States / cities: Westlake Village, California • Hollywood, Florida • Jupiter, Florida + 14 more

Conditions: Venous Thromboembolism, Pulmonary Embolism
Interventions: VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Multiple Myeloma
Interventions: Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Hypericum perforatum, Placebo; Drug · Other
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Breast Cancer
Interventions: HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, biopsy, Sterile water placement; Biological · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Anemia, Critical Illness
Interventions: Iron Dextran, Erythropoietin (EPO); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Compare Ecchymosis and Edema for Fibrin Sealant and no Fibrin Sealant
Interventions: Fibrin Sealant (Artiss); Drug
Lead sponsor: Nguyen, Davis B., M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Beverly Hills, California

Search by objective public record fields.

Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Oxytocin Dosage to Decrease Induction Duration

Efficacy of Dehydrated Cell and Protein Concentrate Versus Corticosteroid

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

Graded Insulin Suppression Test P&F

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

The Benefits of Consuming Hummus as an Afternoon Snack

ProGo Menopause Wellbeing Study

Safety and Efficacy of Albiglutide in Type 2 Diabetes

Adaptions and Resiliency to Multi-Stressor OpeRations

Evaluation of Ocular Lens Proteins in Cataract From Individuals With Down Syndrome

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

A Different Approach to Preventing Thrombosis

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

Practical Anemia Bundle for SusTained Blood Recovery

Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift